APLT stock touches 52-week low at $0.49 amid sharp annual decline

Published 03/03/2025, 17:08
APLT stock touches 52-week low at $0.49 amid sharp annual decline

Applied Therapeutics Inc (NASDAQ:APLT) stock has plummeted to a 52-week low, reaching a price level of just $0.49. The micro-cap biotech company, now valued at $57.13 million, shows high volatility with a beta of 1.88. According to InvestingPro analysis, the stock appears undervalued at current levels. This significant drop reflects a stark contrast to the company’s performance over the past year, with the 1-year change data revealing a precipitous decline of -92.88%. Investors have watched the stock’s value erode steadily, culminating in this latest low point, which has raised concerns about the company’s future prospects and overall market sentiment towards the biopharmaceutical firm. Despite the decline, analyst price targets range from $1.50 to $13, with the next earnings report due March 14. InvestingPro subscribers can access 13 additional key insights and a comprehensive Pro Research Report for deeper analysis of APLT’s financial health and future potential.

In other recent news, Applied Digital Corporation reported fiscal second-quarter results that exceeded analyst expectations. The company achieved adjusted earnings per share of -$0.06, surpassing the anticipated -$0.14, and revenue reached $63.9 million, slightly above the forecasted $63.39 million. A significant contributor to this growth was the Cloud Services segment, which saw a 523% year-over-year increase in revenue, totaling $27.7 million. Meanwhile, the Data Center Hosting business generated $36.2 million in revenue. Applied Digital also announced a $5 billion perpetual preferred equity financing facility with Macquarie Asset Management to bolster its high-performance computing business.

In other developments, Applied Therapeutics, Inc. received a notification from the Nasdaq Stock Market regarding non-compliance with the minimum bid price requirement. The company has been given until August 6, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 per share for ten consecutive business days. If unsuccessful, Applied Therapeutics may seek an additional 180-day extension by transferring its listing to the Nasdaq Capital Market. The company’s executive team is currently evaluating options to address this issue, although no specific course of action has been decided.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.